{
  "id": 12144157,
  "title": "vTv Therapeutics completes Phase 3 enrollment for T1D drug",
  "url": "https://urgent.news/2026/10/05/vtv-therapeutics-completes-phase-3-enrollment-for-t1d-drug",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-05T12:04:32.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/vtv-therapeutics-completes-phase-3-enrollment-for-t1d-drug-93CH-4931981"
  },
  "original_language": "en",
  "account": "vTv Therapeutics, a biopharmaceutical company, has successfully enrolled 166 patients in its Phase 3 clinical trial for a new diabetes medication. The study, known as CATT1, is examining cadisegliatin, an oral glucokinase activator, as an additional treatment for type 1 diabetes when used alongside insulin injections or continuous subcutaneous insulin infusion. The drug, which has received Breakthrough Therapy designation from the FDA, is administered orally in three different dosages: 800 mg once daily, 800 mg twice daily, or a placebo. The primary goal of the study is to determine the incidence of hypoglycemic events over a six-month period, while secondary endpoints include changes in hemoglobin A1c levels, time spent within a target glucose range, and the occurrence of diabetic ketoacidosis compared to placebo. The company anticipates releasing initial results in mid-2027. The study's participants are individuals aged 18 and above who have been diagnosed with type 1 diabetes and are currently on insulin therapy. Cadisegliatin, a novel drug candidate, is being investigated as a potential first-in-class adjunctive treatment for type 1 diabetes, but its safety and efficacy have yet to be established.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Citi raises Kymera Therapeutics stock price target on drug potential",
        "url": "https://urgent.news/2026/10/05/citi-raises-kymera-therapeutics-stock-price-target-on-drug-potential",
        "published": "2026-10-05T09:50:52.000Z"
      },
      {
        "outlet": "CNBC",
        "title": "Harley-Davidson has struggled in recent years. Citi says buy the stock",
        "url": "https://urgent.news/2026/10/05/harley-davidson-has-struggled-in-recent-years-citi-says-buy-the-stock",
        "published": "2026-10-05T10:05:07.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}